A mathematical model of malignant glioma treated by alloCTL (CD8+ cytotoxic T-cell) immunotherapy describing the quantitative interactions of six components tumor cells, CTLs IFNgamma and TGFbeta Major Histocompatibility Complex (MHC) class I receptor on a tumor cells and MHC class II receptor on antigen presenting cells has already been proposed [33,34]. This evidence concerns the gene TGFB1 and malignant glioma.